STAT Plus: How Amgen plans to BiTE into CAR-T’s hype
AMGEN
Greg Friberg, a vice president at Amgen overseeing oncology global development, spoke about the science behind BiTES and the hope for future therapies.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario